CNBX Pharmaceuticals, Inc.

Lust Cherry Rose and Thrust Watermelon Goji aim to make good sex greater SMITHS FALLS, ON, Oct. 21, 2022 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or "the Company") (TSX: WEED) (NASDAQ: CGC), a world-leading diversified cannabis and cannabinoid-based consumer product company, today announced an extension of its Ace Valley brand portfolio with the launch of Lust Cherry Rose and Thrust Watermelon Goji. These two new, distinctly-flavoured, gummies are the first of their kind in the Canadian market, celebrating the intersection of cannabis and sex positivity by empowering consumers to enhance their personal experiences. Continue Reading Ace Valley Lust Cherry Rose Gummies (CNW Group/Canopy Growth Corporation) Ace Valley Thrust Watermelon Goji Gummies (CNW Group/Canopy Growth Corporation) Ace Valley Lust Cherry Rose Gummies (CNW Group/Canopy Growth Corporation) Ace Valley Thrust Watermelon Goji Gummies (CNW Group/Canopy Growth Corporation) In an online survey1, 75 percent of participants said they use cannabis to enhance sex, and 42 percent of participants said they already use cannabis to connect with their partner. The flavours of Lust and Thrust aim to enhance both solo and partnered play via delicious bite-sized gummies and aspire to make good sex greater. Ace Valley Lust Cherry Rose Gummies feature a juicy flavour, botanical extracts and are infused with 25mg of CBD and 2.5mg of THC per gummy, with the sweet, yet delicate, taste of cherry and rose blossoms. Each gummy also features a cool tingle on your tongue, activating your senses. Ace Valley Thrust Watermelon Goji Gummies are infused with 5mg THC per gummy, each with a burst of watermelon and a tickle of goji berry flavour, along with a hint of naturally occurring caffeine. "Ace Valley celebrates sex positivity, including those who are already combining cannabis and sex, as well as those who are curious about it," said Tara Rozalowsky, Vice President, Brand Marketing. "Lust and Thrust gummies were created with pleasure in mind, and both products are a natural extension of Ace Valley's innovative portfolio, which elevates experiences and empowers consumers to use cannabis their way, on their terms." Earlier this year, Ace Valley introduced the first-ever CBN gummies in Canada with Blackberry Lemon Dream, designed with your nighttime routine in mind. The introduction of Lust and Thrust further amplifies the brand's commitment to purposeful consumption and empowering the pleasures of the plant. Ace Valley Lust and Thrust gummies are available for purchase via legal recreational cannabis e-commerce channels and retail locations in select regions. For more information, please visit AceValley.com. About Canopy Growth Corporation Canopy Growth (TSX:WEED, NASDAQ:CGC) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high-quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States, and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional hemp-derived CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information, visit . SOURCE Canopy Growth Corporation

REHOVOT, Israel and BETHESDA, Md., Oct. 13, 2022 /PRNewswire/ - CNBX Pharmaceuticals Inc. (OTC-QB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company's patent application titled "COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS" was filed on October 12, 2022 with the US Patent and Trademark Office (USPTO) and with the Israel Patent Office under a national phase of International Patent Application. National phase filing in Europe will follow. Said patent application relates to several of the drug candidates on the Company's pipeline for the treatment of various types of cancer, including CNBX RCC-33, for the treatment of colorectal cancer currently being developed and prepared for a pre-IND meeting with the FDA and a first-in-human Phase I/II(a) validation study. The company's growing IP portfolio includes 8 patent families, with 7 granted patents and 18 additional pending. The company's IP portfolio is focused on cancer patients and cancer treatments, and includes claims relating to Pharmaceutical Compositions, Methods and Systems. Recent News: CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate CNBX Pharmaceuticals Announces New Patent Granted in Australia About CNBX Pharmaceuticals: CNBX Pharmaceuticals Inc. (OTC-QB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit . For the latest updates on CNBX Pharmaceuticals follow the Company on Twitter@cnbxpharma, Facebook@cnbxPharmaceuticals, LinkedIn , and on Instagram @CNBX_Pharmaceuticals. Disclaimer: Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source. For more information about CNBX: CNBX Pharmaceuticals Inc. +1 (877) 424-2429 info@cnbxpharma.com Logo: Company Codes: OTC-BB:CNBX, OTC-QB:CNBX

REHOVOT, Israel and BETHESDA, Md., Sept. 29, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. ( OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the peer-reviewed publication of its sponsored preclinical study titled "The Effect of Isolated Cannabinoid Extracts on Polypoid Colorectal Tissue" in the International Journal of Molecular Sciences; concluding "possible future therapeutic value" for the company's proprietary drug candidate currently under development, PLP-33, for the treatment of colonic polyps. Study design included collection of both polypoid tissue biopsies and healthy colonic tissue biopsies from 22 patients. A synergistic interaction of cannabinoid compounds against colonic polyps was observed, as well as a differential toxic effect between polypoid tissue and healthy colonic mucosa in some of the cases, thus "suggesting possible future therapeutic value". The present study was led by Gastroenterologists Dr. Dana Ben-Ami Shor (MD), and Dr. Erez Scapa (MD) of the Tel Aviv Sourasky Medical Center in Israel. The abstract and full text of the article titled "The Effect of Isolated Cannabinoid Extracts on Polypoid Colorectal Tissue", published on the International Journal of Molecular Sciences, can be accessed in the following link: . CNBX Pharmaceuticals is currently developing its proprietary Drug Candidate PLP-33 for the treatment of colonic polyps. This activity is conducted in collaboration with Digestix Bioscience Inc. (a CNBX Pharmaceuticals subsidiary). About CNBX Pharmaceuticals: CNBX Pharmaceuticals Inc. ( OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit . For the latest updates on CNBX Pharmaceuticals follow the Company on Twitter @cnbxpharma, Facebook @cnbxPharmaceuticals, LinkedIn, and on Instagram @CNBX_Pharmaceuticals. Disclaimer: Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source. For more information about CNBX: CNBX Pharmaceuticals Inc. +1 (877) 424-2429 [email protected] Logo - SOURCE CNBX Pharmaceuticals Inc.